ClinicalTrials.gg
CompletedNCT04360915Updated Apr 29, 2020

Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects

A Phase 1 interventional study of ASK120067 and ASK120067 in fed condition in Locally Advanced or Metastatic NSCLC, sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-29.

Sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd. (part of Beijing Aosaikang Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2019, registered Apr 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
39th of 41
24 · median 60
Started
2019
with 1 other
Phase 1
4 of 41
1 open now
Registered
3rd of 41
by date
Lead sponsor
4 of 41
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 39th largest by enrollment, is one of 2 that started in 2019, is one of 4 in phase 1, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About aflutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

To evaluate the pharmacokinetic characteristics of ASK120067 and CCB4580030 after the single oral administration of ASK120067 in fast and after a high-fat meal in healthy Chinese subjects, and to evaluate the effect of food on the bioavailability of ASK120067.To evaluate the safety of ASK120067 tablets administered orally in fast and fed.

03

Conditions studied

  • Locally Advanced or Metastatic NSCLC
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Healthy subjects aged 18 or above and 45 or below, male and female;
    1. The weight of male subjects shall not be less than 50 kg, and that of female subjects shall not be less than 45 kg. (BMI) = weight (kg)/height2 (m2), BMI = Within the range of 19.0\~26.0 (including the critical value);
    1. Normal or abnormal physical examination (physical examination, vital signs, laboratory examination, 12-lead , frontal and lateral chest radiographs, etc.) during the screening period has no clinical significance;
    1. Subjects (including male subjects) are willing to have no pregnancy plan from the screening date to 6 months after the last dose, and are willing to take effective measures;
    1. Subjects should sign the before the test, fully understand the test content, process and possible adverse reactions, have good communication with researchers and complete the test according to the test plan.

Exclusion criteria

Exclusion Criteria:

    1. patients with clinical significance who are abnormal by comprehensive physical examination, vital signs examination, routine laboratory examination (blood routine, urine routine, blood biochemistry, coagulation function), 12-lead , and positive and lateral chest radiographs;
    1. HBSAg HCVAb HIVAb, treponema palliatum antibody and other test results were positive;
    1. interphase abnormality (QTc>450ms) with clinical significance;
    1. participated in the drug clinical trial within 3 months before the trial;
    1. taking any medication 14 days before the trial;
    1. surgical resection history, such as: hepatectomy, nephrectomy, digestive organ (gallbladder) resection;
    1. history of tuberculosis;
    1. past history of deep vein thrombosis/other thromboembolic events, abnormal coagulation factors, thrombocytopenia, or abnormal function;
    1. previous history of interstitial lung disease (ILD), drug-induced ILD, radioactive pneumonia requiring treatment, or clinically active ILD with evidence;
    1. allergic or hypersensitive to ASK120067 experimental active ingredients or inactive , drugs with similar chemical structure to the experimental drugs or drugs with the same target, allergic to two or more drugs and food;
    1. there are swallowing difficulties or gastrointestinal diseases affecting drug absorption;
    1. have any disease that increases the risk of bleeding, such as acute gastritis or gastric and duodenal ulcers;
    1. habitual constipation or diarrhea;
    1. heavy drinking and/or a history of excessive drinking (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
    1. alcohol breath test > 0.0mg /100mL;
    1. drug abuse screening positive;
    1. smoking history, smoking more than 5 cigarettes per day in the first 3 months of the screening period or habitual use of nicotine-containing products, and unable to quit during the trial;
    1. those with positive urine nicotine detection results at the screening stage;
    1. having a history of blood or needle sickness;
    1. habitual consumption and consumption of special diet (including grapefruit juice, star fruit, pitaya fruit, etc.) within 7 days before the test, or the presence of other factors affecting drug absorption, distribution, metabolism, excretion, etc.;
    1. blood donation or massive blood loss (> 400 mL) within 3 months prior to the trial;
    1. an acute illness or accident occurs during the screening period;
    1. the female subjects were lactating, or the pregnancy test results were positive, or they had unprotected sex within 2 weeks before the screening date;
    1. there are other conditions that the researcher thinks are not suitable for inclusion.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    ASK120067 in fast condition

    Take ASK120067 tablets orally once in the first day at 160mg in fast condition.

    Drug: ASK120067

  • Experimental
    ASK120067 in fed condition

    Take ASK120067 tablets orally once in the first day at 160mg in fed condition.

    Dietary Supplement: ASK120067 in fed condition

Interventions

  • DrugASK120067

    Drug pages: ASK-120067 · Aflutinib

    Take ASK120067 tablets orally in first day at 160 mg in fast condition.

  • Dietary supplementASK120067 in fed condition

    Drug pages: ASK-120067 · Aflutinib

    Take ASK120067 tablets orally in first day at 160 mg in fed condition.

06

What researchers measure

Primary outcomes

  1. Cmax

    Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out maximum concentration

    Time frame: Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)

  2. AUC

    Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out area under the plasma concentration-time curve

    Time frame: Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)

Secondary outcomes

  1. Tmax

    Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out time to reach maximum concentration

    Time frame: Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)

  2. t1/2

    Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent end elimination half-life

    Time frame: Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)

  3. CL/F

    Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent clearance

    Time frame: Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)

  4. Vd/F

    Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent volume of distribution

    Time frame: Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)

  5. λz

    Collect plasma concentrations of ASK120067 and 1 metabolites following single dose at designated time points of Day 1 to figure out apparent terminal elimination rate constant

    Time frame: Blood samples will be collected from each subject at pre-specified times after the administration of the study on Day 1, (pre-dose, 0.25h,0.5h, 1h,1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 12h, 24h,36h,48h,72 hours post dose)

  6. Incidence and Severity of Treatment-Emergent Adverse Events

    Assessed by number and severity of adverse events as recorded on the case report form.

    Time frame: Adverse events will be collected from baseline until 12 days after the administration and the follow-up period

07

Study locations

1 site
  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Dec 2019, 0 months.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 0 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2020
First posted
Apr 24, 2020
StartActual
Dec 9, 2019
Primary completionActual
Dec 30, 2019
CompletionActual
Dec 30, 2019
Last update
Apr 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04360915
Responsible party
Sponsor
First posted
Apr 24, 2020
Start date
Dec 9, 2019
Primary completion
Dec 30, 2019
Completion
Dec 30, 2019
Last update
Apr 29, 2020

Study contacts

Zourong Ruan
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ASK-120067 · Aflutinib

Start the discussion